Search
Results: 6
Patterns of alternative access
Olga Löblová, Marcell Csanádi, Piotr Ozierański, Zoltán Kaló, Lawrence King, Martin McKee
Aug 21, 2019
Many countries employ "alternative access schemes" (e.g. compassionate use, early access programs, off-label use) that seek to provide patients with access to drugs not included on a positive drug list. These schemes offer...
The effects of releasing early results from ongoing clinical trials.
Steffen Ventz, Sergio Bacallado, Rifaquat Rahman, Sara Tolaney, Jonathan D Schoenfeld, Brian M Alexander, Lorenzo Trippa
Feb 05, 2021
Most trials do not release interim summaries on efficacy and toxicity of the experimental treatments being tested, with this information only released to the public after the trial has ended. While early release of clinical...
Do drugs offering only PFS maintain quality of life sufficiently from a patient's perspective? Results from AVALPROFS (Assessing the 'VALue' to patients of PROgression Free Survival) study.
V Jenkins, V Farewell, S May, S Catt, L Matthews, V Shilling, J Dickson, R Simcock, L Fallowfield
Sep 10, 2018
PURPOSE: Trials of novel drugs used in advanced disease often show only progression-free survival or modest overall survival benefits. Hypothetical studies suggest that stabilisation of metastatic disease and/or symptom burden...
patients’ views Progression-Free Survival Quality of life Side effects Adult Aged Aged 80 and over Antineoplastic Combined Chemotherapy Protocols Attitude to Health Disease Progression Disease-Free Survival drugs Investigational Female Humans Immunotherapy Male Middle Aged Neoplasm Metastasis Neoplasms Perception Quality of life Surveys and Questionnaires Treatment Outcome
Accelerating drug development for neuroblastoma
Lucas Moreno, Giuseppe Barone, Steven G DuBois, Jan Molenaar, Matthias Fischer, Johannes Schulte, Angelika Eggert, Gudrun Schleiermacher, Frank Speleman, Louis Chesler, Birgit Geoerger, Michael D Hogarty, Meredith S Irwin, Nick Bird, Guy B Blanchard, Sean Buckland, Hubert Caron, Susan Davis, Bram De Wilde, Hedwig E Deubzer, Emmy Dolman, Martin Eilers, Rani E George, Sally George, Štěrba Jaroslav, John M Maris, Lynley Marshall, Melinda Merchant, Peter Mortimer, Cormac Owens, Anna Philpott, Evon Poon, Jerry W Shay, Roberto Tonelli, Dominique Valteau-Couanet, Gilles Vassal, Julie R Park, Andrew DJ Pearson
Jul 29, 2020
Only one class of targeted agents (anti-GD2 antibodies) has been incorporated into front-line therapy for neuroblastoma since the 1980s. The Neuroblastoma New Drug Development Strategy (NDDS) initiative commenced in 2012 to...
Clinical Trials Drug development epigenetics MYCN Neuroblastoma phase I Preclinical testing Antineoplastic Agents Brain Neoplasms Child Congresses as Topic Drug development Drug Discovery Europe Humans Medical Oncology Molecular Targeted Therapy Neuroblastoma Pediatrics Protein Kinase Inhibitors therapies Investigational
Current and emerging therapeutic approaches for T-cell acute lymphoblastic leukaemia.
leukaemia novel treatments Antineoplastic Agents Antineoplastic Agents Immunological Apoptosis Arabinonucleosides Bridged Bicyclo Compounds Heterocyclic Cyclin-Dependent Kinases Genetic Heterogeneity Humans Immunotherapy Immunotherapy Adoptive Janus Kinase Inhibitors Molecular Targeted Therapy Neoplasm Proteins Phosphoinositide-3 Kinase Inhibitors Precursor T-Cell Lymphoblastic Leukemia-Lymphoma Protein Kinase Inhibitors Protein-Tyrosine Kinases Receptor Notch1 Receptors Interleukin-7 Salvage therapy Signal Transduction Sulfonamides therapies Investigational Treatment Outcome
Diabetic retinopathy
Michael Whitehead, Sanjeewa Wickremasinghe, Andrew Osborne, Peter van Wijngaarden, Keith R Martin
Dec 12, 2018